Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Depreciation & Amortization (CF) (2019 - 2022)

Cyclerion Therapeutics (CYCN) has 4 years of Depreciation & Amortization (CF) data on record, last reported at $17000.0 in Q2 2022.

  • For Q2 2022, Depreciation & Amortization (CF) fell 83.0% year-over-year to $17000.0; the TTM value through Mar 2023 reached $17000.0, down 93.03%, while the annual FY2022 figure was $65000.0, 86.23% down from the prior year.
  • Depreciation & Amortization (CF) reached $17000.0 in Q2 2022 per CYCN's latest filing, down from $48000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $800000.0 in Q2 2019 and bottomed at $17000.0 in Q2 2022.
  • Average Depreciation & Amortization (CF) over 4 years is $390785.7, with a median of $486500.0 recorded in 2019.
  • Peak YoY movement for Depreciation & Amortization (CF): increased 25.2% in 2020, then plummeted 92.0% in 2021.
  • A 4-year view of Depreciation & Amortization (CF) shows it stood at $653000.0 in 2019, then fell by 27.57% to $473000.0 in 2020, then plummeted by 89.85% to $48000.0 in 2021, then tumbled by 64.58% to $17000.0 in 2022.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $17000.0 in Q2 2022, $48000.0 in Q1 2022, and $48000.0 in Q4 2021.